Waffle House Implements 50 Cent Surcharge on Each Egg Due to Supply Issues Caused by Bird Flu
Waffle House has temporarily raised its prices as the highly pathogenic avian influenza (HPAI) know as bird flu ravages the nation's farms.
On Monday, Feb. 3, the restaurant chain implemented a temporary $0.50 surcharge for every egg ordered amid supply issues caused by the current bird flu outbreak.
"The continuing egg shortage caused by HPAI (Bird Flu) has caused a dramatic increase in egg prices. Consumers and restaurants are being forced to make difficult decisions," a memo shared with Nextstar reads.
The PEOPLE Puzzler crossword is here! How quickly can you solve it? Play now!
While Waffle House did not give an end date for the per egg surcharge, it said that it is intended to be 'a temporary targeted surcharge tied to the unprecedented rise in egg prices."
"While we hope these price fluctuations will be short-lived we cannot predict how long this shortage will last,' the memo said, per Nextstar.
Related: Bird Flu Detected in Milk Sold in California, State Health Officials Say
Eggs are Waffle House's most popular item. According to its website, it serves 272 million eggs per year, followed by hashbrowns (153 million) and waffles (124 million). PEOPLE reached out to Waffle House for comment.
Data from the U.S. Bureau of Labor Statistics shows that in January 2024, the average price of grade A large eggs per dozen was $2.52.
While the price has fluctuated since then, it was $4.15 by December 2024. According to the U.S. Department of Agriculture, egg prices are predicted to increase 20.3% in 2025.
While the current bird flu outbreak began in 2020 and reached the United States in 2022, it spiked in recent months.
Per the Centers for Disease Control (CDC), as of Feb. 4, 2025, 16 states have H5N1 (avian flu) outbreaks in dairy cows with 957 dairy herds affected. The agency also reports 51 jurisdictions with poultry outbreaks, and a staggering 153 million poultry affected. Bird flu has also been reported in 51 jurisdictions and detected in 11,000 wild birds.
Related: Florida Dolphin Found 'In Distress' Later Diagnosed with Bird Flu, Study Finds
Last April, the World Health Organization expressed 'enormous concern' about the potential spread of the bird flu to humans.
'This is a huge concern and I think we have to … make sure that if H5N1 did come across to humans with human-to-human transmission, that we were in a position to immediately respond with access equitably to vaccines, therapeutics and diagnostics,' said Dr. Jeremy Farrar, WHO's chief scientist, according to a United Nations report.
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
While there is no evidence that bird flu can be transmitted from human to human, as of February 2024, there have been 67 cases of bird flu in humans in the United States and one death.
Amid the escalating outbreak, the Trump administration ordered a pause on all communications made by federal health agencies including the Centers for Disease Control and Prevention, per CNN. The pause has prevented important studies on bird flu and its transmission from being published.
Read the original article on People
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Patents and economies of scale support Pfizer's wide moat
Pfizer's innovative business should grow faster after it divests its off-patent division Upjohn in 2020 to create Viatris and Mylan. With fewer older medications and fewer patent losses, Pfizer is well-positioned for consistent growth, excluding the erratic sales of Covid-19-related products. The company is less vulnerable to any one patent loss thanks to its wide range of medications. Because of its more complex manufacturing process and more affordable prices, Pfizer's stronger position in the vaccine marketwhich includes the pneumococcal vaccine Prevnarmakes it more resilient to generic competition. Warning! GuruFocus has detected 6 Warning Signs with PFE. With a 30% to 80% reduction, Trump's executive order would establish a "most favored nation" policy in which the US would pay the same amount for prescription medications as the nation with the lowest price. It is anticipated that this policy, which was previously blocked by courts, will reduce the US's annual drug spending of over $400 billion, saving taxpayers over a seven-year period. Given that drug prices in the United States are high when compared to other countries, Pfizer's U.S. revenue could be drastically impacted by the 30% to 80% price cut, especially for high-margin medications. International reference pricing policies have long been opposed by the pharmaceutical industry, which claims they could hinder innovation and limit access to new companies anticipate that the order will target Medicare and may have an impact on medications not covered by Biden's Inflation Reduction Act. President Trump has said that significant tariffs on pharmaceutical products will probably be announced soon. He has also put a 90-day hold on broader tariffs for the majority of his trading partners to give them time to negotiate. Despite being mostly exempt from tariffs, the biopharma industry is preparing for a possible pharma-specific announcement that might affect global manufacturing strategies. Products made in Europe and imported into the US may be subject to the rumored 25% tariff, necessitating the construction of new facilities that will take years to complete. Due to home country manufacturing, tax benefits, lower production costs, and exposure to currency fluctuations, businesses based in the US and Europe are heavily exposed to European manufacturing. Because drug spending is not cyclical, the direct effect of tariffs on earnings is probably going to be minimal, and the indirect effect of a possible recession should also be minimal. With the exception of small-scale US capacity expansions, biopharma is unlikely to completely reevaluate its manufacturing footprint if pharmaceutical tariffs are implemented but are lifted after 2026 as a result of political pressure from the midterm elections. Leadership in Vaccines Pfizer stands out with its dominant position in vaccines, most notably its highly successful COVID-19 vaccine developed in partnership with BioNTech. This vaccine not only generated significant revenue but also established Pfizer as a leader in mRNA technology, a platform with potential applications in oncology, rare diseases, and beyond. Johnson & Johnson (J&J): J&J also developed a COVID-19 vaccine, but it was less widely adopted due to lower efficacy rates and safety concerns, giving Pfizer a clear advantage in this high-impact area. GlaxoSmithKline (GSK): GSK has a strong vaccine portfolio (e.g., shingles and meningitis vaccines) but did not independently develop a COVID-19 vaccine, relying on partnerships like Sanofi, which delayed its entry and diminished its competitive stance. Bristol Myers Squibb (BMS): BMS has no significant presence in vaccines, focusing instead on oncology and immunology, making Pfizer's vaccine leadership a unique strength. R&D Capabilities and Pipeline Focus Pfizer's R&D efforts are concentrated on high-growth therapeutic areas such as oncology, vaccines, and rare diseases. Its ability to leverage mRNA technology and rapidly develop innovative therapies underscores its R&D prowess. J&J: J&J's R&D spans pharmaceuticals, medical devices, and consumer health. While this diversification provides stability, it may dilute J&J's focus on cutting-edge pharmaceutical innovation compared to Pfizer's targeted approach. GSK: GSK excels in respiratory diseases and HIV research, but its pipeline is less broad and lacks the same level of innovation in emerging technologies like mRNA that Pfizer is advancing. BMS: BMS has a strong oncology pipeline, particularly in immuno-oncology, but its narrower focus limits its competitiveness in other high-growth areas where Pfizer thrives, such as vaccines and rare diseases. Global Reach and Market Presence Pfizer operates in over 150 countries, giving it a vast global footprint that enhances its ability to distribute products and capture market share across both developed and emerging markets. J&J: J&J also has a global presence, but its focus is split across pharmaceuticals, medical devices, and consumer health, potentially reducing its pharmaceutical market penetration compared to Pfizer. GSK: GSK is strong in Europe and emerging markets but less dominant in the U.S., the world's largest pharmaceutical market, where Pfizer has a significant advantage. BMS: BMS focuses heavily on the U.S. and Europe, with less presence in emerging markets, limiting its global scale compared to Pfizer. Brand Reputation and Trust The success of Pfizer's COVID-19 vaccine has significantly boosted its brand recognition and trust among consumers, healthcare providers, and governments, reinforcing its market position. J&J: J&J enjoys a strong reputation in consumer health, but its pharmaceutical division lacks the same level of visibility and trust as Pfizer's, particularly after COVID-19 vaccine challenges. GSK: GSK is well-regarded in respiratory and HIV treatments but does not have the broad public recognition that Pfizer has achieved. BMS: BMS is respected in oncology but lacks the widespread brand prominence that Pfizer has cultivated. Innovation in Emerging Technologies Pfizer's investment in mRNA technology positions it as a pioneer in pharmaceutical innovation, with potential applications in vaccines, cancer treatments, and more, giving it a forward-looking edge. J&J: J&J innovates in medical devices and consumer health but trails Pfizer in adopting next-generation pharmaceutical technologies like mRNA. GSK: GSK focuses on innovation in respiratory and HIV treatments but has not made significant advances in mRNA or other emerging platforms. BMS: BMS drives innovation in immuno-oncology but lacks Pfizer's breadth and leadership in cutting-edge technologies. Pfizer's competitive edge over Johnson & Johnson, GlaxoSmithKline, and Bristol Myers Squibb lies in its unmatched leadership in vaccines, particularly through mRNA technology, combined with a robust R&D pipeline, extensive global reach, substantial financial resources, strong brand reputation, and a focus on innovation. While J&J benefits from diversification, GSK from efficiency, and BMS from oncology expertise, none rival Pfizer's comprehensive strengths across these critical areas, ensuring its dominance in the pharmaceutical landscape. Pfizer's broad moat is supported by patents, economies of scale, and a strong distribution network. Strong pricing power derived from Pfizer's patent-protected medications allows the company to produce returns on investment that exceed its cost of capital. The company can develop the next generation of drugs before generic competition appears thanks to the patents. Furthermore, even though Pfizer has a wide range of products, there is some product concentration, as Prevnar accounts for slightly more than 10% of total sales (not including sales of the COVID-19 vaccine).However, because of the vaccine's complicated manufacturing process and comparatively low cost, we don't anticipate typical generic competition. Ibrance and Eliquis each account for nearly 10% of sales. On the other hand, we anticipate that new products will eventually lessen the competition from generic versions of important medications. In order to lessen the pressure on margins from lost sales of high-margin drugs, Pfizer's operating structure permits cost-cutting after patent losses. All things considered, Pfizer's well-established product line generates the massive cash flows required to cover the typical $800 million in development expenses for each new medication. For smaller pharmaceutical companies without Pfizer's resources, the company's robust distribution network positions it as a solid partner. On April 15, President Donald Trump issued an executive order outlining possible policy changes intended to reduce the cost of pharmaceuticals in the United States. The biopharma industry is looking forward to these changes because they have the potential to either help or hurt innovation. In the worst situation, international price benchmarks have the potential to drastically cut US drug prices and lessen financial incentives for international drug development. On the plus side, eliminating the "pill penalty" that only grants small molecule medications nine years of Medicare negotiation protection may promote innovation across all treatment modalities. Trump's executive order may have a positive or negative impact on the industry, but it has no effect on valuations or uncertainty ratings. The protection period is not specified in Trump's request that US Department of Health and Human Services Secretary Robert F. Kennedy Jr. collaborate with Congress to address the pill penalty, which is contingent upon Congressional action. Since innovation and a favorable mergers and acquisitions climate support long-term pricing power and offset possible short-term tariff pressure, rising tax rates, and approval delays, the biopharma industry seems undervalued. Due to liver damage in a clinical trial, Pfizer has announced the discontinuation of danuglipron, an oral small molecule GLP-1 agonist. In the anticipated $200 billion global GLP-1 market by 2031, the company sought to provide a potential second-to-market oral small molecule GLP-1 agonist, behind Lilly's orforglipron. Clinical trial failures and declining demand for Pfizer's COVID vaccine and antiviral medication have hurt the company's growth. Because of its diverse pipeline and portfolio, Pfizer is expected to have a wide-moat case, protecting it from the effects of individual program failures, especially those involving high-risk programs like danuglipron. Other medication candidates might benefit from Pfizer's objective of turning danuglipron into a once-daily business could use its $15 billion acquisition budget to fund the development of more sophisticated medication candidates. Efforts in Genetic Engineering: A solid growth driver for Pfizer is the strong pipeline of innovative treatment options, especially in oncology and immunology, which take the leap with cutting-edge scientific technology. To be more specific, Pfizer's resource allocation to immuno-oncology is evident, developing of checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) and chimeric antigen receptor T-cell (CAR-T) therapies. For instance, this method of treatment mitigates the immune system's ability to detect and destroy the specified cancer cells by varying the immune system response or, in some cases, by using specially modified T-cells that can identify the particular antigens on tumors that are solely expressed in those particular tumors, which are in question. This is the area of advancement where Pfizer has outdone the rest as they are perfecting monoclonal antibody formatsdesigning them in a way that they will bind more tightly and specifically to targets using protein engineeringand they are also testing out bispecific antibodies that trigger switches at two targets, therefore enhancing healing by more than one method. The pipeline is further supported by vast R&D investment in gene therapy and precision medicine, which utilize adeno-associated virus (AAV) vector platforms for gene delivery and next-generation sequencing for actionable mutation identification respectively. These endeavors are aimed at enhancing the overall patient health and market potential of the drugs by changing the treatment convention from testing a wide spectrum to one that is genotype-driven. Clinical trials are usually designed in a way to be fast-tracked so that they can move quickly to the next stage of development. By focusing on such advanced technologies, Pfizer is embarking on capturing a large section of the market with high-growth therapeutic branches, thus gaining revenue through innovation guided by complex disease biology. Revenue Growth: The launching of these high-value treatments is expected to increase revenue as well as drive down costs for Pfizer. Most of the drugs that are released in the onco-immunology field possess a technical edge and therapeutic effectiveness, therefore, these new treatements often demand high price. These drugs are capable of pumping up profits significantly once they clear regulatory hurdles and find their way onto the market. take the example of just-above successful immuno-oncology drug sales, which always have brisk selling and marvelous sales. In addition, Pfizer can speed-up the whole clinical process with something like adaptive trial designs, this process will be quicker and thus benefits are obtained faster from the new products. Impact on profitability The weight on profitability depends on the ratio of costs and returns. What is actually known is that lamas like the checkpoint inhibitors and CAR-T treatments that are so good require a lot of investment in R&D. But there is an inherent advantage for these drugs thanks to their patent protection that comes with market exclusivity, which in turn, allows Pfizer to keep its pricing strategy stick and generate very high profits. Success in the selling of the product along the lines of this new dimension along with the efficiency of producing more could prove to be the road to better profitability. However, there are barriers such as competition from other drug companies plus the worry of the price cuts from payers that can erode this success. So if Pfizer is able to eliminate the competition and stays ahead in the game by reducing costs as well, these high markups brought about by the introduction of such innovative drugs should positively affect the total profitability of the company. Generic competition, possible changes to government drug pricing policies, the more stringent FDA, and more powerful managed-care and pharmacy benefit managers present Pfizer with difficulties in drug development. In some disease areas, developing new drugs is getting harder, and pharmacy benefit managers and managed-care organizations have grown to be strong players with the ability to bargain for cheaper drug costs. Nearly one-fourth of the company's total sales are generated by its medications, Eliquis, Ibrance, and Xtandi, and they are heavily exposed to the Medicare channel. Given that Pfizer's product portfolio is less vulnerable to potential litigation, the company's base-case annual legal costs, assuming a 50% probability of future costs associated with product governance ESG risks, come close to 1% of non-GAAP net income. Pfizer's valuation multiples highlights their strong financial position and potential undervaluation. Their P/E Non-GAAP ratios7.61 (FY1), 7.42 (FY2), and 7.44 (FY3)are lower than JNJ's 14.00 (FY1) and SNY's 10.80 (FY1), suggesting investors may undervalue our earnings potential. The PEG Non-GAAP (FWD) of 1.49 is competitive, higher than SNY's 0.76 but below JNJ's 1.70, reflecting moderate growth prospects. Pfizer's EV/Sales (TTM) of 2.81 is more conservative than JNJ's 4.21, while the EV/EBITDA (FWD) of 7.13 compares favorably to JNJ's 11.45, indicating operational efficiency. The Price to Book (TTM) of 1.44 is significantly lower than JNJ's 5.23, and our Price to Cash Flow (TTM) of 9.29 beats JNJ's 15.67, underscoring robust cash flow generation. These metrics position Pfizer as a value opportunity among peers After the Seagen acquisition, Pfizer released its 2024 guidance, which included a $8 billion COVID-19 product guidance$5 billion less than anticipated. The business admitted that, excluding sales of COVID-19 products, it would not meet the prior growth-rate projection of 6% from 2020 to 2025. Pfizer reaffirmed its support for the dividend, which is regarded as safe and likely to boost stock valuation, despite the deteriorating outlook. Over the next ten years, the company anticipates steady sales as new products counteract older medications that are losing their patent protection. From the middle of 2023 to the end of 2024, Pfizer is anticipated to reduce operating expenses by $4 billion, which will aid the company in adjusting to the waning pandemic and declining sales of COVID-19 products. Growth could be accelerated through acquisitions, and future margin pressure could be reduced through restructuring initiatives. It is estimated that Pfizer's weighted average cost of capital is 7% and its cost of equity is 7.5%. Activist investor Jeffrey Smith's recent stake worth $407 million could presage the much needed turnarounds at Pfizer. Investors and shareholders can reasonably expect further cost-cuts and an efficient use of capital, leading to higher margins and free cashflow. This case could follow the path of Walt Disney, albeit with less drama, where Jeff Ubben of ValueAct had a pivotal role in Disney's turnaround campaign. The large-cap biopharma company Pfizer's debt size, business cyclicality, and debt maturity outlook all contribute to its sound balance sheet and low risk levels. To support opportunistic acquisitions and handle product litigation issues with little market concern, the company should have a strong enough balance sheet. Pfizer spends slightly less on R&D than the industry average, with a mid- to high-teens percentage of sales. Patent losses are offset by the company's robust pipeline of next-generation medications. The company's investment in cutting-edge new medications, mostly aimed at immunology and oncology, improves its standing and increases returns on capital. For biopharma companies in the sector, this balance sheet strength is essential. This article first appeared on GuruFocus. Sign in to access your portfolio
Hamilton Spectator
37 minutes ago
- Hamilton Spectator
Trump's big bill also seeks to undo the big bills of Biden and Obama
WASHINGTON (AP) — Chiseling away at President Barack Obama's Affordable Care Act . Rolling back the green energy tax breaks from President Joe Biden's Inflation Reduction Act . At its core, the Republican 'big, beautiful bill' is more than just an extension of tax breaks approved during President Donald Trump's first term at the White House. The package is an attempt by Republicans to undo, little by little, the signature domestic achievements of the past two Democratic presidents. 'We're going to do what we said we were going to do,' Speaker Mike Johnson said after House passage last month. While the aim of the sprawling 1,000-page plus bill is to preserve an estimated $4.5 trillion in tax cuts that would otherwise expire at year's end if Congress fails to act — and add some new ones, including no taxes on tips — the spending cuts pointed at the Democratic-led programs are causing the most political turmoil. The nonpartisan Congressional Budget Office said this week that 10.9 million fewer people would have health insurance under the GOP bill, including 1.4 million immigrants in the U.S. without legal status who are in state-funded programs. At the same time, lawmakers are being hounded by businesses in states across the nation who rely on the green energy tax breaks for their projects. As the package moves from the House to the Senate, the simmering unrest over curbing the Obama and Biden policies shows just how politically difficult it can be to slash government programs once they become part of civic life. 'When he asked me, what do you think the prospects are for passage in the Senate? I said, good — if we don't cut Medicaid,' said Sen. Josh Hawley, R-Mo., recounting his conversation last week with Trump. 'And he said, I'm 100% supportive of that.' Health care worries Not a single Republican in Congress voted for the Affordable Care Act, known as Obamacare, in 2010, or Biden's inflation act in 2022. Both were approved using the same budget reconciliation process now being employed by Republicans to steamroll Trump's bill past the opposition. Even still, sizable coalitions of GOP lawmakers are forming to protect aspects of both of those programs as they ripple into the lives of millions of Americans. Hawley, Sen. Lisa Murkowski of Alaska and others are wary of changes to Medicaid and other provisions in the bill that would result in fewer people being able to access health care programs. At the same time, crossover groupings of House and Senate Republicans have launched an aggressive campaign to preserve, at least for some time, the green energy tax breaks that business interests in their states are relying on to develop solar, wind and other types of energy production. Murkowski said one area she's 'worried about' is the House bill's provision that any project not under construction within 60 days of the bill becoming law may no longer be eligible for those credits. 'These are some of the things we're working on,' she said. The concerns are running in sometimes opposite directions and complicating the work of GOP leaders who have almost no votes to spare in the House and Senate as they try to hoist the package over Democratic opposition and onto the president's desk by the Fourth of July. While some Republicans are working to preserve the programs from cuts, the budget hawks want steeper reductions to stem the nation's debt load. The CBO said the package would add $2.4 trillion to deficits over the decade. After a robust private meeting with Trump at the White House this week, Republican senators said they were working to keep the bill on track as they amend it for their own priorities. Senate Majority Leader John Thune said the president 'made the pitch and the argument for why we need to get the bill done.' The disconnect is reminiscent of Trump's first term, when Republicans promised to repeal and replace Obamacare, only to see their effort collapse in dramatic fashion when the late Sen. John McCain, R-Ariz, voted thumbs down for the bill on the House floor. Battle over Medicaid In the 15 years since Obamacare became law, access to health care has grown substantially. Some 80 million people are now enrolled in Medicaid, and the Kaiser Family Foundation reports 41 states have opted to expand their coverage. The Affordable Care Act expanded Medicaid to all adults with incomes up to about $21,500 for an individual, or almost $29,000 for a two-person household. While Republicans no longer campaign on ending Obamacare , advocates warn that the changes proposed in the big bill will trim back at access to health care. The bill proposes new 80 hours of monthly work or community service requirements for able-bodied Medicaid recipients, age 18 to 64, with some exceptions. It also imposes twice-a-year eligibility verification checks and other changes. Republicans argue that they want to right-size Medicaid to root out waste, fraud and abuse and ensure it's there for those who need it most, often citing women and children. 'Medicaid was built to be a temporary safety net for people who genuinely need it — young, pregnant women, single mothers, the disabled, the elderly,' Johnson told The Associated Press. 'But when when they expanded under Obamacare, it not only thwarted the purpose of the program, it started draining resources.' Initially, the House bill proposed starting the work requirements in January 2029, as Trump's term in the White House would be coming to a close. But conservatives from the House Freedom Caucus negotiated for a quicker start date, in December 2026, to start the spending reductions sooner. Senate Democratic Leader Chuck Schumer has said the changes are an Obamacare rollback by another name. 'It decimates our health care system, decimates our clean energy system,' Schumer of New York said in an interview with the AP. The green energy tax breaks involve not only those used by buyers of electric vehicles, like Elon Musk's Tesla line, but also the production and investment tax credits for developers of renewables and other energy sources. The House bill had initially proposed a phaseout of those credits over the next several years. But again the conservative Freedom Caucus engineered the faster wind-down — within 60 days of the bill's passage. 'Not a single Republican voted for the Green New Scam subsidies,' wrote Sen. Mike Lee, R-Utah, on social media. 'Not a single Republican should vote to keep them.' 'REPEAL THE GREEN NEW SCAM!' reposted Rep. Chip Roy, R-Texas, a Freedom Caucus leader. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Yahoo
38 minutes ago
- Yahoo
Vietnam Inks Deals to Buy $3 Billion US Products Before Talks
(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here. Next Stop: Rancho Cucamonga! Where Public Transit Systems Are Bouncing Back Around the World ICE Moves to DNA-Test Families Targeted for Deportation with New Contract US Housing Agency Vulnerable to Fraud After DOGE Cuts, Documents Warn Trump Said He Fired the National Portrait Gallery Director. She's Still There. Vietnamese businesses have signed 20 agreements worth about $3 billion to import more US agricultural products ahead of the third round of official negotiations set to take place next week. Memoranda of understanding were signed during talks involving Minister of Agriculture and Environment Do Duc Duy in Iowa, Ohio, Maryland and Washington from June 2-6, the ministry said in a statement on Saturday. 'These agreements highlight the strong commitment and goodwill of Vietnam's business community and government to promote balanced trade with the US, and to encourage the Trump administration to reconsider high reciprocal tariffs on Vietnamese goods,' it said. Vietnam has engaged in weeks of intense diplomacy with the US — the largest export market of the trade-reliant country — as it seeks to avert a threatened 46% tariff, which was later wound back to 10% for 90 days to allow time for talks. The reference to 'goodwill' echoes language used earlier this week, when the Southeast Asian nation sent a written reply to US trade requests after the Trump administration vowed to keep pressuring the country to reduce its role in China supply chains. Vietnam cited progress after the second round of trade talks last month but said that outstanding issues remain. It's taken steps to address some US concerns, such as stepping up a crackdown on trade fraud and promising to buy US agricultural products. Cavs Owner Dan Gilbert Wants to Donate His Billions—and Walk Again The SEC Pinned Its Hack on a Few Hapless Day Traders. The Full Story Is Far More Troubling YouTube Is Swallowing TV Whole, and It's Coming for the Sitcom Is Elon Musk's Political Capital Spent? Trump Considers Deporting Migrants to Rwanda After the UK Decides Not To ©2025 Bloomberg L.P.
